Background {#Sec1}
==========

Alzheimer's disease (AD) is a neurodegenerative disease and the most common form of dementia. Although its etiology is not completely understood, a genetic component of susceptibility to AD has been shown in the literature \[[@CR1]--[@CR6]\]. Cerebrospinal fluid (CSF) studies \[[@CR7]--[@CR10]\] have also been conducted in AD to identify differential biomarkers. Given that one hallmark of AD pathology is a cerebral accumulation of amyloid-β 1--42 peptide (Aβ~1--42~) in amyloid plaques, the Aβ~1--42~ level has been shown markedly reduced in CSF. In addition, the total tau (t-tau) protein level has been shown significantly elevated in the CSF of AD patients. As a result, the CSF t-tau/Aβ~1--42~ ratio has also been studied as a biomarker for differentiating AD from normal older adults \[[@CR5], [@CR11]--[@CR13]\].

With the recent advances in high-throughput genotyping technologies, Genome-Wide Association Studies (GWAS) have been applied to the analysis of CSF biomarkers (e.g., \[[@CR13], [@CR14]\]) to identify relevant genetic markers, such as Single Nucleotide Polymorphisms (SNPs). While most studies examined genetic associations with CSF biomarkers at the individual SNP or gene level, mining higher level genetic associations using biological interaction networks is still an under-explored topic for the CSF biomarker studies in AD. Recently, many studies in other domains have demonstrated that integrative analyses of GWAS data and protein-protein interaction (PPI) networks can provide valuable biological insights. Some methods have been proposed to identify subnetworks enriched by GWAS results \[[@CR15]--[@CR19]\]. One tool is iPINBPA \[[@CR16], [@CR20]--[@CR23]\], which is based on the fact that the genes identified in GWAS are more likely to physically interact as well as to belong to the same or related pathways.

With these observations, in this work, we performed a genome-wide network-based pathway analysis for CSF studies in AD. We analyzed an AD cohort from Alzheimer's Disease Neuroimaging Initiative (ADNI), used the CSF biomarker t-tau/Aβ~1--42~ ratio as the test phenotype or quantitative trait (QT), downloaded the PPI network from the Human Protein Reference Database (HPRD) (<http://www.hprd.org/>), and applied the iPINBPA analysis to the GWAS findings of the CSF t-tau/Aβ~1--42~ ratio. Our goal was to search for subnetworks or network modules enriched by the CSF GWAS findings, which may offer valuable biological insights and suggest high confidence candidates for subsequent analyses.

Methods {#Sec2}
=======

Figure [1](#Fig1){ref-type="fig"} illustrates the work-flow of this study. The genotyping and CSF data were downloaded from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. GWAS of the CSF QT was performed using the PLINK software \[[@CR24]\]. This resulted in 563,980 SNPs with associated *p*-values, which were then assigned to 22,179 genes. The gene assignment and gene-based p-values were calculated using the VEGAS2 software \[[@CR25]\]. The nominally significant genes (i.e., gene-based *p*-values ≤ 0.05) were mapped onto the HPRD PPI network \[[@CR26], [@CR27]\] and analyzed using the iPINBPA method in order to identify the enriched subnetworks. The Enrichr pathway analysis tool \[[@CR28]\] was applied to functionally annotate the subnetwork.Fig. 1Flow chart. Step1: GWAS using Plink was performed on 843 ADNI participants. Step2: VEGAS2 was used to obtain gene-level p-values, which were mapped onto the HPRD PPI network. Step3: Network-based analysis was performed by iPINBPA software 10 times, and 10 groups of subnetworks were obtained. For the top subnetwork of each result, we computed a consensus module by intersecting this top subnetwork with the most similar subnetworks obtained in all the other nine results. Step4: KEGG pathway enrichment analysis was performed for each consensus module by Enrichr tool.

Subjects {#Sec3}
--------

Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). One goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early AD. For up-to-date information, see <http://adni.loni.usc.edu/>. Appropriate Institutional Review Boards approval occurred at each ADNI site and informed consent was obtained from each participant or authorized representative.

In this study, our analyses were concentrated on 843 ADNI subjects whose genotyping data (after quality control described below) and the baseline CSF biomarker data including t-tau and Aβ~1--42~ were both available. This sample included 199 cognitively normal (CN) subjects, 85 subjects with significant memory concern (SMC), 239 subjects with early mild cognitive impairment (EMCI), 207 subjects with late mild cognitive impairment (LMCI), and 113 subjects with Alzheimer's disease (AD). Table [1](#Tab1){ref-type="table"} shows the demographic and clinical characteristics of these participants at the baseline, where the characteristics were analyzed with the statistical software IBM SPSS \[[@CR29]\] Version 2 for differences across diagnostic groups using one-way analysis of variance (ANOVA) or Chi-square test.Table 1Selected demographic and clinical characteristics of 843ADNI participantsCN\
(*N* = 199)SMC\
(*N* = 85)EMCI\
(*N* = 239)LMCI\
(*N* = 207)AD\
(*N* = 113)*P*-valueAge (years)74.4 (5.79)72.0(5.48)71.4(7.30)72.4(7.62)75.2 (8.19)*p* \< 0.001Women\*96(48%)50(59%)102(43%)83(40%)45(40%)0.002\*Education (years)16.2 (2.82)16(2.79)16.2(2.84)16.4(2.53)16.4(2.56)0.764APOE e4 allele present47(24%)31(36%)99 (41%)112(54%)74 (65%)*p* \< 0.001CDR-SOB0.04(0.14)0.08(0.18)1.27(0.77)1.65(0.94)4.53 (1.70)*p* \< 0.001Mini mental status examination29.1(1.18)29.0(1.2)28.3(1.62)27.5(1.75)23.1 (2.05)*p* \< 0.001Logical memory immediate\
recall14.42(3.00)14.44(3.34)11.09(2.68)7.18(3.06)4.15 (2.70)*p* \< 0.001Logical memory delayed\
recall13.34(3.13)13.29(3.31)8.97(1.73)3.94 (2.7)1.52 (1.80)*p* \< 0.001t-tau/Aβ~1-42~Ratio\
(i.e., QT for GWAS)0.40 (0.27)0.37(0.24)0.50(0.45)0.70(0.47)0.98 (0.49)*p* \< 0.001*AD* Alzheimer's disease, *ADNI* Alzheimer's Disease Neuroimaging Initiative, *CDR--SOB* clinical dementia rating--sum of boxes, *CN* cognitively normal, *SMC* significant memory concern, *EMCI* early mild cognitive impairment, *LMCI* late mild cognitive impairment. Number (%) or mean (s.d.) was shown in each entry. *P*-values were assessed due to significant differences between diagnosis groups, which computed using one-way ANOVA (\*except for gender using chi-square test)

CSF Biomarker Measurement as Quantitative Trait {#Sec4}
-----------------------------------------------

The amyloid-β 1--42 peptide (Aβ~1--42~) and total tau (t-tau) measured in the baseline CSF samples of the participants were downloaded from the ADNI database. The t-tau/Aβ~1--42~ ratio was computed and used as the quantitative trait in the GWAS.

Genotyping Data and Quality Control {#Sec5}
-----------------------------------

The genotyping data of the participants were collected using either the Illumina 2.5 M array (a byproduct of the ADNI whole genome sequencing sample) or the Illumina OmniQuad array. For the present analyses, single nucleotide polymorphism (SNP) markers that were present on both arrays were included \[[@CR6], [@CR30], [@CR31]\].

Quality control (QC) was performed on the ADNI participants using the PLINK v1.07 software \[[@CR24]\] (<http://zzz.bwh.harvard.edu/plink/>), following a similar procedure described in Li et al. \[[@CR32]\]. Briefly, SNPs not meeting any of the following criteria were excluded: (1) SNPs available on both 2.5 M array and OmniQuad array, (2) call rate per SNP ≥ 95%; (3) minor allele frequency ≥ 5% (n = 1,845,510 SNPs were excluded based on Criteria 1--3); and (4) Hardy-Weinberg equilibrium test of *p* ≥ 10^−6^ (*n* = 198 SNPs were excluded) using control subjects only. Participants were excluded from the analysis if any of the following criteria were not satisfied: (1) call rate per subject ≥ 95% (no participant was excluded), (2) sex check (1 participant was excluded), (3) identity check for related pairs (8 sibling pairs and 1 sibling triple were identified with PI_HAT \>0.5, 1 participant from each family was randomly selected and included in the study).

Population stratification analysis was performed using EIGENSTRAT \[[@CR33]\], and confirmed using STRUCTURE \[[@CR34]\]. It yielded 89 study participants who did not cluster with the remaining subjects and with the CEU HapMap samples who are primarily of European ancestry (non-Hispanic Caucasians). These 89 participants were excluded from the analysis. After QC, 563,980 SNPs and 843 individuals remained available for the subsequent GWAS, network and pathway analyses.

SNP-Level and Gene-Level GWAS Analyses {#Sec6}
--------------------------------------

For GWAS, to examine the main effects, linear regression was implemented by PLINK to evaluate the association between each SNP and the t-tau/Aβ~1--42~ ratio. An additive genetic model was tested with covariates, including age, gender, and diagnosis (through five binary dummy variables indicating CN, SMC, EMCI, LMCI, and AD). Then, the SNP-level *p*-values were obtained.

The VEGAS2 software \[[@CR25]\] was used to assign 563,980 SNPs to 22,179 autosomal genes according to positions on the UCSC Genome Browser (out of 26,292 in hg19), and to compute gene-level p values. The software applies simulations from the multivariate normal distribution to employ information from a defined subset of markers within a gene as well as take into account linkage disequilibrium between the markers. To save running time, we use a multi-stage approach to adaptively determine the number of simulations per gene: (Stage 1) we run 10^3^ simulations for all the genes; (Stage 2) we run 10^4^ simulations only for genes with Stage 1 empirical *p*-values ≤ 0.1; (Stage 3) we run 10^6^ simulations only for genes with Stage 2 empirical *p*-values ≤ 0.001. We interpret an empirical *p*-value of 0 from 10^6^ simulations as *p* \< 10^−6^. Given 22,179 genes included in this analysis, a Bonferroni-corrected threshold is *p* \< 2.25 × 10^−6^ (i.e., 0.05/22,179), which can be exceeded by the theoretically smallest empirical *p*-value shown above. A Manhattan plot was generated using R ([http://www.r-project.org](http://www.r-project.org/)) to visualize the gene-level GWAS results for our work.

Network-level Analysis {#Sec7}
----------------------

The Human PPI data (*n* = 9,617) were downloaded from the Human Protein Reference Database (HPRD, [http://www.hprd.org](http://www.hprd.org/)); gene-level *p*-values obtained from the GWAS of the CSF t-tau/Aβ~1--42~ ratio were mapped to the PPI network. The integrative protein interaction network-based pathway analysis (iPINBPA) software \[[@CR22]\] was used to integrate GWAS findings with physical evidence of interaction at the protein level, and to detect new high-level associations (i.e., subnetworks of functionally interacted genes) with the CSF biomarker. Briefly, iPINBPA identifies enriched subnetworks using the following three steps.

In Step 1, using the GWAS findings, the nominally significant genes (i.e., *p* ≤ 0.05) are treated as seed genes, and assigned with certain weights (e.g., in this work, *1* for seed genes, *0* for the rest). After that, a random walk with restart strategy is employed to smooth these weights over the entire network. Intuitively, the nodes in the network are weighted based on their connectivity to seed genes (i.e., guilt-by-association). Let n~k~ be a node on the PPI network mapped with gene-level *p*-value p~i~. Let e~ij~ be the edge connecting n~i~ and n~j~, and W~ij~ be the weight of e~ij~. All the W~ij~'s form the adjacency matrix W. Extending Köhler's approach \[[@CR35]\], iPINBPA weights the edge e~ij~ as follows:$$\documentclass[12pt]{minimal}
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In addition, it normalizes the adjacency matrix W by its columns. After each step of random walk, a score vector is calculated as$$\documentclass[12pt]{minimal}
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where P(t) is the score after walking t steps, and r is the restart ratio. In this work, we assign *1* to all the seed genes, and *0* to the rest. Upon the completion of the random walk after *T* steps, the vector *P(T)* contains the node weights, which reflect the topological connections to the seed genes \[[@CR36]\].

In Step 2, given a network *A* containing *k* nodes, iPINBPA defines its score by combining the gene-level *p*-values with node weights described above, using the Liptak-Stouffer method. Specifically, the network score of *A* is defined, via weighted Z transform test \[[@CR37]\], as follows:
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A random sampling of gene sets of size *k*∈\[1, 500\] for 1000 times was applied in iPINBPA \[[@CR36]\] to determine the background distribution of the network score. Using this distribution, the adjusted network score of *A* is defined as:
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where Z~A~ is the network score, and *μ* ~*k*~ and *σ* ~*k*~ are respectively the mean and the standard deviation of the background distribution of the network scores at size *k*.

In Step 3, a greedy algorithm was developed to search for modules with high network scores, i.e., those enriched in genes with low *p*-values and high weights. Details about the algorithm is available in Wang et al. \[[@CR22]\].

In this work, the parameters were set in iPINBPA as follows: r = 0.5, T = 5, NetScore \> 3.0, NetSize ≥ 5, and MaxNetSize ≤ 300. Given the stochastic nature of the iPINBPA algorithm, we ran iPINBPA ten times, respectively by setting the random seed value from 1 to 10. Consequently, we obtained ten groups of enriched subnetworks (GNs) identified by iPINBPA. Below, we couple a consensus module (CM) strategy with iPINBPA (named as CM-iPINBPA) to generate consensus findings from these analyses.

Given two subnetworks *m* and *n*, we use Dice's coefficient *DC(m,n)* to measure their similarity:
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In this work, we only focused on analyzing the top subnetwork (TN) in each iPINBPA run. Let *TN* ~*a*~ be the top subnetwork identified in Run *a* ∈ {1, 2, ..., 10}. We first find *SN* ~*b*~ *(TN* ~*a*~ *)*, which is the most similar subnetwork to *TN* ~*a*~ in Run *b* ∈ {1, 2, ..., 10}\\{*a*}. Clearly we have$$\documentclass[12pt]{minimal}
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where *sn* is any subnetwork enriched in Run *b*. After that, we define the consensus module (CM) based on Run *a* as follows:

*CM* ~*a*~ = *TN* ~*a*~ ∩ (∩~*a* ≠ *b*,*b* ∈ {1,2,...,10}~ *SN* ~*b*~(*TN* ~*a*~)).

Namely, *CM* ~*a*~ is the intersection of *TN* ~*a*~ and its most similar subnetworks identified in all the other runs.

Network Module Visualization and Functional Analysis {#Sec8}
----------------------------------------------------

Cytoscape 3.2 \[[@CR38]\] was used to visualize the example identified network modules. The Enrichr \[[@CR28]\] pathway analysis tool (<http://amp.pharm.mssm.edu/Enrichr/>) and the Kyoto Encyclopedia of Genes and Genomes database (KEGG; <http://www.genome.jp/kegg/>) \[[@CR39]\] was applied to functional analysis of the identified network modules. Heat map was plotted, using R 3.2.0 software, to demonstrate relations between consensus modules and relevant KEGG pathways.

Results {#Sec9}
=======

GWAS and gene-level analysis {#Sec10}
----------------------------

The demographic and clinical characteristics for the 843 ADNI subjects in this study are presented in Table [1](#Tab1){ref-type="table"}. The summary statistics for all diagnostic groups (CN, SMC, EMCI, LMCI, and AD) are given. Education level (*p* = 0.764) was not significantly different across the five diagnostic groups; however, gender demonstrated a significant difference (*p* = 0.002). Furthermore, as expected, age, *APOE* e4 status, clinical dementia rating--sum of boxes (CDR-SOB), mini mental status examination (MMSE), logical memory immediate recall, and logical memory delayed recall exhibited significant differences across the five groups (*p* \< 0.001). Also as expected, the phenotype t-tau/Aβ~1--42~ ratio significantly differed across the diagnostic groups (*p* \< 0.001).

The top SNP in the GWAS analysis was rs4420638 (chromosome 19, 14 kb away from the *APOC1* gene, *p* = 2.576E-28), which was previously reported by Lars Bertram et al. \[[@CR40]\]. The SNP rs769449 within the *APOE* gene on chromosome 19 was also significant with *p* = 4.98E-23, and was previously reported by Soerensen et al. \[[@CR41]\]. Similar to the results reported in our earlier paper \[[@CR13]\], The *TOMM40* SNP rs2075650 (chromosome 19, *p* =4.23E-18, was associated with t-tau/Aβ~1--42~ ratio.

Under the hypothesis that genes, rather than SNPs, are the functional units in biology \[[@CR42]\], a gene-level association analysis of the t-tau/Aβ~1--42~ ratio was performed based on the SNP-level results by VEGAS2. Table [2](#Tab2){ref-type="table"} shows the top 10 genes identified by VEGAS2. Figure [2](#Fig2){ref-type="fig"} shows the Manhattan plot of the gene-based GWAS results.Table 2The top 10 genes identified by VEGAS2ChrGenenSNPsTest*P*valueTopSNPTopSNP-*P*value19APOC16274.961.00E-06rs44206382.58E-2819APOE7188.921.00E-06rs7694494.98E-2319PVRL219228.011.00E-06rs20756504.23E-1819TOMM4011363.851.00E-06rs7694494.98E-2317PDK211103.375.00E-06rs38097621.86E-0617ITGA315111.817.40E-05rs38097621.86E-0619CBLC224.351.12E-04rs29651211.45E-0417CCL7528.842.38E-04rs9918042.28E-0419KLK71256.022.76E-04rs110840437.74E-051PTGER397400.303.07E-04rs75408681.89E-04Chr: Chromosome; Gene: Gene name; nSNPs: Number of SNPs in the input file that map to the gene; Test: The sum of the individual chi-squared 1 degree of freedom SNP-association test statistic; Pvalue: The gene-based p-value considering the full set of SNPs; TopSNP: The name of the most significant SNP within the gene; TopSNP-Pvalue: The p-value for the most significant SNP with the gene Fig. 2**a** Manhattan plot showing the gene-level p values in ADNI t-tau/Aβ~1--42~ ratio GWAS study. The blue line corresponds to *p* = 10^−5^; the red line corresponds to *p* = 10^−6^. Bonferroni-corrected threshold is p \< 2.25 × 10^−6^ (i.e., 0.05/22,179)

Network search for CMs {#Sec11}
----------------------

Consensus modules (CMs) were identified by CM-iPINBPA network analysis strategy. Subnetwork search was conducted on the GWAS findings using iPINBPA ten times by varying the seed value of random number generator, which ranged from 1 to 10. Table [3](#Tab3){ref-type="table"} summarizes the results of ten iPINBPA runs. *PRKCA* and *TP53* appeared to be the start nodes of the top subnetworks identified in multiple runs. The *PRKCA* gene was previously reported as being associated with an altered amyloid precursor protein (APP) secretion in fibroblasts from AD patients \[[@CR43], [@CR44]\]. Culmsee et al. demonstrated that *TP53* was a novel gene as a biomarker of AD and was related to neurodegenerative processes \[[@CR45]\].Table 3Results of 10 iPINBPA runsSRN\# of SubnetworksTN SizeTNStartNodeTN Score1105899PRKCA10.11291892PRKCA9.703975151TP5310.9541100133-10.525977108PRKCA9.856936135-10.6471166101PRKCA9.4181050147-11.27997267TP538.0410955146-11.25SRN:The seed value used for an iPINBPA run\# of Subnetworks: The number of subnetworks identified in an iPINBPA runTN Size: The number of genes in the top subnetwork identified in an iPINBPA runTN StartNode: The start node of the top subnetworkTN Score: The score of the top subnetwork

Table [4](#Tab4){ref-type="table"} shows the top subnetwork identified in each run, its most similar subnetworks in other runs coupled with the Dice's coefficient value, and the corresponding CM. For example, in Table [4](#Tab4){ref-type="table"}, the Dice's coefficient between TN1 and SN1 (in GN~2~) is 0.96335. Thanks to the overlapping subnetworks, only four unique CMs were identified (Table [4](#Tab4){ref-type="table"}). These four CMs are shown in Fig. [3](#Fig3){ref-type="fig"}, where the reddish nodes represent the known AD genes from the KEGG AD pathway (hsa05010). CM1 (*S* ~*A*~ = 10.15, p \< 0.001) shown in Fig. [3(a)](#Fig3){ref-type="fig"} contains totally 67 genes, including KEGG AD genes *GSK3B, MAPK1, PSEN2, CALM1, CALM2* and *CASP8*. CM2 (*S* ~*A*~ = 10.39, p \< 0.001) shown in Fig. [3(b)](#Fig3){ref-type="fig"} contains totally 67 genes, including KEGG AD genes *BACE1, GSK3B, MAPK1, PSEN2, CALM1, CALM2* and *CASP8*. CM3 (*S* ~*A*~ = 7.99, *p* \< 0.001) shown in Fig. [3(c)](#Fig3){ref-type="fig"} contains 40 genes, including KEGG AD genes *GSK3B*, *CALM1* and *CASP8*. CM4 (*S* ~*A*~ = 10.46, *p* \< 0.001) shown in Fig. [3(d)](#Fig3){ref-type="fig"} contains 58 genes, including KEGG AD genes *BACE1*, *GSK3B*, *MAPK1*, *PSEN2*, *CALM1*, *CALM2* and *CASP8*.Table 4The characteristics of the identified consensus modules in 10 iPINBPA runsCMRunATa: the top subnetwork in RunA. Sb: the most similar subnetwork to Ta in RunBRunB1234567891011Rank of Sb in RunB1143161384DC(Ta, Sb)1.000.960.880.880.960.960.990.820.810.9612Rank of Sb in RunB1143161384DC(Ta, Sb)0.961.000.850.850.921.000.950.780.840.9223Rank of Sb in RunB3212323215DC(Ta, Sb)0.780.771.000.930.830.910.810.970.610.8334Rank of Sb in RunB23212121131DC(Ta, Sb)0.850.820.971.000.890.990.860.950.670.9515Rank of Sb in RunB1143161384DC(Ta, Sb)0.960.920.930.931.000.920.970.860.771.0036Rank of Sb in RunB23212121131DC(Ta, Sb)0.840.820.980.990.881.000.860.960.660.9617Rank of Sb in RunB1143161384DC(Ta, Sb)0.990.950.890.890.970.951.000.830.800.9738Rank of Sb in RunB23212121131DC(Ta, Sb)0.800.780.980.950.840.960.811.000.631.0049Rank of Sb in RunB3212383215DC(Ta, Sb)0.820.830.610.680.770.730.790.641.000.77310Rank of Sb in RunB23212121131DC(Ta, Sb)0.800.780.980.950.850.960.821.000.631.00*CM* consensus module id, *DC* Dice's coefficient Fig. 3Consensus modules identified by 10 runs of iPINBPA. **a** Consensus Module1; **b** Consensus Module 2; (c) Consensus Module 3; (d) Consensus Module 4. The reddish color indicates genes belonging to the KEGG Alzheimer's Pathway. The adjusted network scores (i.e., *S* ~*A*~) of these four modules are 10.15, 10.39, 7.99, and 10.46, respectively. Therefore, all the modules are significant (*p* \< 0.001)

In addition, the intersection of the four CMs was extracted and named as the common subnetwork. The common subnetwork is shown in Fig. [5](#Fig5){ref-type="fig"}, and contains total 29 genes, including 3 KEGG AD genes *CALM1, CASP8,* and *GSK3B,* and 26 other genes.

Pathway analysis of consensus modules and the common subnetwork {#Sec12}
---------------------------------------------------------------

To test the hypothesis that CMs enriched by the GWAS findings might be significantly overrepresented in AD and other relevant pathways, the Enrichr method was performed for pathway analysis. For the genes in each CM, a pathway enrichment analysis was conducted, and the nominally enriched pathways were identified with adjusted *p*-value ≤ 0.05. Then, these identified pathways of the four CMs were plotted as a heat map shown in Fig. [4](#Fig4){ref-type="fig"} to summarize the relationships between the pathways and CMs. Note that Fig. [4](#Fig4){ref-type="fig"} lists only pathways enriched by at least one CM. Table [5](#Tab5){ref-type="table"} shows top 20 pathway enrichments analysis of the common subnetwork.Fig. 4Functional annotation of the four identified consensus modules (CM1-CM4) using KEGG pathways. The four consensus modules were treated as four gene sets, and went through pathway enrichment analysis based on the KEGG pathway database. The enrichment results at a nominal statistical threshold of adjusted *p*-value \< 0.05 are shown. -log~10~(p-value) values are color-mapped and displayed in the heat map. Heat map blocks labeled with "x" reach the nominal significance level of adjusted *p*-value \< 0.05. Only top enrichment findings are included in the heat map, and so each row (pathway) has at least one "x" block Table 5Top 20 pathway enrichments analysis of the common consensus subnetworkPathwayOverlap*P*-valueAdjusted *P*-valueZ-scoreCombined ScoreGenesglioma4/627.19E-050.002277−2.1413.00PDGFRB; PIK3R1;CALM1;TP53apoptosis4/811.94E-040.002277−1.8511.28CASP8; CFLAR;PIK3R1;TP53huntingtons disease3/312.20E-040.002277−1.7710.77CASP8;CALM1;TP53colorectal cancer4/842.22E-040.002277−1.8411.18PDGFRB; GSK3B;PIK3R1;TP53prostate cancer4/862.42E-040.002277−1.8010.97PDGFRB; GSK3B;PIK3R1;TP53endometrial cancer3/529.23E-040.007232−1.658.13GSK3B;PIK3R1;TP53renal cell carcinoma3/692.02E-030.01286−1.616.99GAB1;PIK3R1;HIF1Amelanoma3/712.19E-030.01286−1.496.50PDGFRB;PIK3R1;TP53erbb signaling pathway3/853.59E-030.018769−1.536.08GSK3B;GAB1;PIK3R1focal adhesion4/1924.51E-030.02118−1.606.16PDGFRB; GSK3B;PIK3R1;RHOAneurodegenerative diseases2/389.01E-030.038512−0.872.83NGFR;CASP8non small cell lung cancer2/531.66E-020.064347−1.213.32PIK3R1;TP53basal cell carcinoma2/551.78E-020.064347−0.922.53GSK3B;TP53b cell receptor signaling pathway2/622.22E-020.074377−0.912.37GSK3B;PIK3R1phosphatidylinositol signaling system2/722.91E-020.081711−1.002.50PIK3R1;CALM1pancreatic cancer2/732.98E-020.081711−0.992.49PIK3R1;TP53chronic myeloid leukemia2/753.13E-020.081711−0.932.33PIK3R1;TP53adherens junction2/753.13E-020.081711−0.781.96CSNK2A1;RHOAregulation of actin cytoskeleton3/2013.54E-020.087678−0.962.34PDGFRB; PIK3R1;RHOAsmall cell lung cancer2/853.92E-020.092081−0.731.74PIK3R1;TP53Pathway: The name of KEGG pathwayOverlap: The number of overlapping genes compared with the number of input genes*P*-value: *P*-value was computed using the Fisher exact testAdjusted P-value: Adjusted *P*-value was a corrected *p*-value to the Fisher exact testZ-score: Computed by assessing the deviation from the expected rankCombined score: Computed by taking the log of the *p*-value from the Fish exact test and multiplying that by the z-score of the deviation from the expected rankGenes: The overlapping genes between the input and the pathway

Discussion {#Sec13}
==========

Gene-level analysis {#Sec14}
-------------------

In the GWAS analysis, the gene-level *p*-values were determined and shown in Fig. [2](#Fig2){ref-type="fig"}. The use of the CSF t-tau/Aβ~1--42~ ratio as a quantitative trait (QT) in this study enabled us to examine the effect of genes previously known to be associated with the QT as well as to identify novel genes. Table [2](#Tab2){ref-type="table"} lists the top ten genes obtained by converting SNPs into gene-wise *p*-values. Given the Bonferroni-corrected threshold of *p* \< 2.25 × 10^−6^ (i.e., 0.05/22,179), we found five significant genes. As expected, significant associations were identified between loci on chromosome 19 and the CSF t-tau/Aβ~1--42~ ratio (e.g., *APOC1, APOE, PVRL2, TOMM40*, *p* = 1 × 10^−6^, see Fig. [2](#Fig2){ref-type="fig"}). Among these genes, apolipoprotein C1 (ApoC1) encoded by the *APOC1* gene is associated with amyloid β plaques; the *APOE* and *TOMM40* (rs769449) genes code for proteins related to the clearance of Aβ and mitochondrial functions \[[@CR5], [@CR13]\]; and the *PVRL2* gene was previously reported as related to risk factors that contribute to AD pathogenesis \[[@CR46]\]. *PDK2* (*p* = 5 × 10^−6^) shows a trend towards the significance, and the overexpression of this gene may be related to cancer and diabetes\[[@CR47]\]. Additionally, *CCL7* mRNA is highly increased by Aβ~1--42~ stimulation \[[@CR48]\]. The *CCL7* gene was previously reported as related to the chemotaxis of pro-inflammatory cells to the inflamed location \[[@CR49]\]. The *PTGER3* gene was previously reported as being related to the inflammatory response \[[@CR50]\].

Network search for CMs and functional validation {#Sec15}
------------------------------------------------

Although iPINBPA has been successfully applied in several previous studies \[[@CR16], [@CR20]--[@CR23]\], we observed that different subnetworks could be obtained by using different random seed values. To overcome this limitation, we proposed to examine the consensus modules discovered by multiple iPINBPA analyses. In other words, we focused on examining the shared subnetworks among multiple iPINBPA runs, which turned out to be more stable patterns. A two-stage strategy was employed. First, ten groups of subnetworks were generated by running iPINBPA ten times with varying random seed values ranging from 1 to 10. After comparing these ten sets of results, we identified ten CMs, one from each run (defined as the intersection of the top subnetwork from the current run and the most similar subnetworks from all the other runs). As a result, there are four unique CMs based on ten identified ones.

The genes in the CMs might not show a direct statistical significance but could interact with some genes identified in our GWAS. These genes can demonstrate indirect association with the studied QT, and may potentially provide valuable biological interpretation. For example, Consensus Module 1 contains the protein gamma-aminobutyric acid (GABA) A receptor (*GABRB1*) gene. *GABRB1* codes for the β1 subunit of gamma-aminobutyric acid A (GABA~A~) receptors \[[@CR1]\]. The *GABRB1* gene has been demonstrated to be involved in the thalamus structure and its interactive effects on intelligence \[[@CR51]\]. The *GABRB1* gene had also been associated with many neuropsychological diseases, such as schizophrenia, major depression, bipolar disorder, and Alzheimer's disease \[[@CR52]\].

In this study, we hypothesize that trait prioritized CM with high replication might have strong functional associations with t-tau/Aβ~1--42~ ratio. We gathered these identified pathways for 4 CMs to plot heatmap to explore and refine the relationships between pathways and CMs (Fig. [4](#Fig4){ref-type="fig"}). In Fig. [4](#Fig4){ref-type="fig"}, it was observed that four pathways, including colorectal cancer, gliomas, renal cell carcinoma, and Huntington's disease, were commonly enriched in all the consensus modules. The neurodegenerative symptoms of neuron death affect many diseases, including Alzheimer's, Parkinson's, and Huntington's diseases. Below we briefly discuss a few additional pathways identified in Fig. [4](#Fig4){ref-type="fig"}. In AD, focal adhesion complexes regulating neuronal viability can be used in treatment to adjust neuronal survival \[[@CR53]\]. The adherens junction has been demonstrated as maintaining blood--brain barrier integrity, and the adherens junction pathways is highly associated with neurodegenerative diseases \[[@CR54]\]. Apoptosis is an important pathway in Alzheimer's disease that is associated with neuronal loss \[[@CR55]\]. The change in the MAPK signaling pathway contributes to significant change in neurotropin \[[@CR56]\]. Some cancer-related pathways were found, such as colorectal cancer, pancreatic cancer, prostate cancer, endometrial cancer, bladder cancer, and so on. Some prior studies have been performed to examine the relationship between cancer and neurologic disease \[[@CR57], [@CR58]\].

With these observations, the genes in the CMs may provide valuable information to suggest novel molecular mechanisms for subsequent analyses. Compared with the standard iPINBPA method, CM-iPINBPA network analysis strategy for mining consensus models could offer more stable results.

Common subnetwork and functional validation {#Sec16}
-------------------------------------------

The common subnetwork is the intersection of the four identified common modules, and consists of 29 genes (Fig. [5](#Fig5){ref-type="fig"}). Among these genes, the *GSK3B, SUMO1, AKAP5, CALM1* and *DLG4* genes have been identified to be involved in tau phosphorylation, and over-phosphorylation of the tau protein can form the tangles in the brain of AD patients \[[@CR59]--[@CR63]\]. Additionally, the *CASP8, PIK3R1, PPA1, PARP1, CSNK2A1, NGFR,* and *RHOA* genes have been demonstrated to be involved in amyloid beta peptide production \[[@CR64]--[@CR70]\]. The *BCL3, CFLAR, SMAD1,* and *HIF1A* genes have been identified to be associated with late-onset Alzheimer\'s disease. The common subnetwork also contains the following genes *TP53, DDX5, NDN, MST1R, CCDC106, NMT2, RPA1, AKAP13, GAB1, PPM1A, SPTBN1* and *MED6*, which interact with themselves and other genes. These findings offer valuable biological insights and suggest promising candidates for subsequent analyses.Fig. 5The common subnetwork. This subnetwork consists of only overlapping genes of all consensus modules. The reddish color indicates genes belonging to the KEGG Alzheimer's Pathway

Table [5](#Tab5){ref-type="table"} shows the top twenty pathways enriched by the common subnetwork. Some significant pathways were observed, such as glioma, apoptosis, Huntington's disease, renal cell carcinoma, melanoma, the erbb signaling pathway, focal adhesion, neurodegenerative diseases, and so on. Twelve genes (*PDGFRB, PIK3R1, CALM1, CFLAR, TP53, RHOA, CASP8, HIF1A, GSK3B, GAB1, NGFR* and *CSNK2A1*) were involved in the top twenty pathways. The gene *PDGFRB* has been confirmed as causative of primary familial brain calcifications (PFBC) \[[@CR71]\]. The gene *PIK3R1* has been shown to be involved in Alzheimer's disease \[[@CR72]\]. *CALM1* encodes for tau protein and regulates the subcellular localization and function of calmodulin in neurons \[[@CR73]\]. *CFLAR* suppresses death receptor-induced apoptosis and TCR activation, which induces cell death by inhibiting caspase-8 activation \[[@CR74]\]. *RHOA* was implicated in Aβ neurotoxicity, and the activation generates cytoskeletal changes \[[@CR75]\]. *NGFR* ligands play an important role in preventing fundamental tau-related pathologic mechanisms in Alzheimer's disease \[[@CR76]\]. These pathways appear relevant given the results in prior studies. For other genes identified in this pathway analysis, it warrants further investigation to demonstrate the role they play.

Limitations {#Sec17}
-----------

Due to the limited number of subjects available to us, we were only able to perform a discovery study in this work. When more data become available in the future, replication studies in independent cohorts are required to evaluate and validate the identified network modules in our study. In addition, in this work, we reported the results using the default parameter setting provided by the software tool and according to Lili et al. \[[@CR22]\], except the random seed value. We ran iPINBPA multiple times by using different random seed values and then extracting the consensus patterns to stabilize the results. As to other parameters, we also briefly tested each of those by varying its value. For most of these parameters, we obtained very similar results. The most sensitive parameter is the restart ratio used in the step called "random walk with restart" for prioritizing phenotype-associated genes. It is excepted that different restart ratios will assign different weights to network nodes and subsequently produce different scores for network components. The determination of the optimal restart ratio warrants a separate and focused investigation and is an interesting future direction.

Conclusions {#Sec18}
===========

Network-based methods form a new generation of enrichment analysis strategy, and they can overcome the limitation of traditional enrichment analysis where only a fixed set of pre-defined pathways are examined. In this study, a genome-wide network-based pathway analysis of the CSF biomarker of the t-tau/Aβ~1--42~ ratio was performed, using a sample of 843 subjects from the ADNI database. To our knowledge, this is the first genome-wide network-based pathway study on the CSF biomarker t-tau/Aβ~1--42~ ratio in Alzheimer's disease. Due to the stochastic nature of the iPINBPA method, we employed a consensus module (CM) strategy to run iPINBPA multiple times and aimed to identify CMs from these different runs. We identified 4 CMs. These CMs contain not only genes from KEGG AD pathways, including *BACE1, GSK3B, MAPK1, PSEN2, CALM1, CALM2, CASP8,* and *SK3B*; but also interesting genes with relevant biological functions such as *GABRB1*, *MMP2*, *CDK17*, and *IGFBP3*. In sum, besides confirming previous findings (e.g., *APOE*, *TOMM40*, *APOC1*), this study has also suggested new susceptible genes, CMs and pathways underlying Alzheimer's disease.

AD

:   Alzheimer's disease

ADNI

:   Alzheimer's Disease Neuroimaging Initiative

ANOVA

:   Analysis of variance

Aβ~1--42~

:   Amyloid-β 1--42 peptide

CDR-SOB

:   Clinical dementia rating--sum of boxes

CM

:   Consensus module

CM-iPINBPA

:   Consensus module (CM) strategy with iPINBPA

CMs

:   Consensus modules

CN

:   Cognitively normal

CSF

:   Cerebrospinal fluid

DC

:   Dice's coefficient

EMCI

:   Early mild cognitive impairment

GNs

:   Groups of enriched subnetworks

GWAS

:   Genome-Wide Association Studies

HPRD

:   Human Protein Reference Database

iPINBPA

:   Integrative protein interaction network-based pathway analysis

LMCI

:   Late mild cognitive impairment

MCI

:   Mild cognitive impairmen

MMSE

:   Mini mental status examination.

MRI

:   Magnetic resonance imaging

PET

:   Positron emission tomography

PPI

:   Protein-protein interaction

QT

:   Quantitative trait

SMC

:   Significant memory concern

SNPs

:   Single Nucleotide Polymorphisms

TN

:   Top subnetwork

t-tau

:   Total tau

Alzheimer's Disease Neuroimaging Initiative

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>

Funding {#FPar1}
=======

Data analysis, result interpretation and manuscript writing were supported in part by National Key Scientific Instrument and Equipment Development Projects of China (2012YQ04014010), Fundamental Research Funds for the Central Universities (HEUCF160412) and the Natural Science Foundation of Heilongjiang Province (F201241). Data analysis, method development, and manuscript editing were supported in part by NIH R01 LM011360, R01 EB022574, RC2 AG036535, R01 AG19771, P30 AG10133, and NSF IIS-1117335 at IU.

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ([www.fnih.org](http://www.fnih.org/)). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Availability of data and materials {#FPar2}
==================================

The genotyping and CSF data were downloaded from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu/>). Application for access to the ADNI data can be submitted by anyone at <http://adni.loni.usc.edu/data-samples/access-data/>. The process includes completion of an online application form and acceptance of Data Use Agreement. We have received administrative approval for access to the ADNI database. The Human PPI data were downloaded from the public Human Protein Reference Database (<http://www.hprd.org/>).

Authors' contributions {#FPar3}
======================

W.C., J.L., H.L. and L.S. led and supervised the research. X.M., H.L., L.S., W.C., and J.L. designed the research and wrote the article. X.M. performed the gene analysis, network mapping, iPINBPA analysis, and pathway analysis. Q.Z. and F.C. prepared the genotyping and CSF biomarker data, and performed quality control and GWAS. W.L., Y.W., and S.C. helped with research design and data analysis. X.Y., J.Y., S.K., A.J.S. and L.S. provided guidance and consultation on the genotyping and biomarker details about ADNI data, data preprocessing, quality control, population stratification, GWAS protocol, gene analysis, network analysis and pathway analysis. All the authors reviewed, commented and approved the manuscript.

Competing interests {#FPar4}
===================

The authors have no actual or potential conflicts of interest including any financial, personal, or other relationships with other people or organizations that could inappropriately influence (bias) our work.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

The study procedures were approved by the institutional review boards of all participating centers (<https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/> ADNI_Acknowledgement_List.pdf), and written informed consent was obtained from all participants or their authorized representatives. Ethics approval was obtained from the institutional review boards of each institution involved: Oregon Health and Science University; University of Southern California; University of California---San Diego; University of Michigan; Mayo Clinic, Rochester; Baylor College of Medicine; Columbia University Medical Center; Washington University, St. Louis; University of Alabama at Birmingham; Mount Sinai School of Medicine; Rush University Medical Center; Wien Center; Johns Hopkins University; New York University; Duke University Medical Center; University of Pennsylvania; University of Kentucky; University of Pittsburgh; University of Rochester Medical Center; University of California, Irvine; University of Texas Southwestern Medical School; Emory University; University of Kansas, Medical Center; University of California, Los Angeles; Mayo Clinic, Jacksonville; Indiana University; Yale University School of Medicine; McGill University, Montreal-Jewish General Hospital; Sunnybrook Health Sciences, Ontario; U.B.C.Clinic for AD & Related Disorders; Cognitive Neurology---St. Joseph's, Ontario; Cleveland Clinic Lou Ruvo Center for Brain Health; Northwestern University; Premiere Research Inst (Palm Beach Neurology); Georgetown University Medical Center; Brigham and Women's Hospital; Stanford University; Banner Sun Health Research Institute; Boston University; Howard University; Case Western Reserve University; University of California, Davis---Sacramento; Neurological Care of CNY; Parkwood Hospital; University of Wisconsin; University of California, Irvine---BIC; Banner Alzheimer's Institute; Dent Neurologic Institute; Ohio State University; Albany Medical College; Hartford Hospital, Olin Neuropsychiatry Research Center; Dartmouth-Hitchcock Medical Center; Wake Forest University Health Sciences; Rhode Island Hospital; Butler Hospital; UC San Francisco; Medical University South Carolina; St. Joseph's Health Care Nathan Kline Institute; University of Iowa College of Medicine; Cornell University; and University of South Florida: USF Health Byrd Alzheimer's Institute.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
